According to the Zhitong Finance App, Dongyao Pharmaceutical-B (01875) announced its results for the first quarter of 2024. Operating revenue increased 68% year on year to about 223 million yuan, and net profit was about 7.409 million yuan, turning a year-on-year loss into a profit.
According to the announcement, revenue growth was mainly due to a sharp increase in sales of self-developed products and continued growth in the CDMO/CMO business.